Search results
Results from the WOW.Com Content Network
Silodosin received its first marketing approval in Japan in May 2006, [12] [11] under the brand name Urief, which is jointly marketed by Kissei Pharmaceutical and Daiichi Sankyo. Kissei licensed the US, Canadian, and Mexican rights for silodosin to Watson Pharmaceuticals (now Allergan ) in 2004. [ 13 ]
The number of people who benefit from a drug determines if drug trials are worth carrying out, given that phase III trials may cost between $100 million and $700 million per drug. This is the motivation behind personalized medicine , that is, to develop drugs that are adapted to individual patients.
The international nonproprietary name of the drug was inspired by that of Thor's hammer, Mjölnir. The idea is that the drug will strike down the virus like a mighty blow from the god of thunder. [30] In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) approved moving molnupiravir into Phase I clinical trials for ...
A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. [ 1 ] [ 2 ] Drug therapy ( pharmacotherapy ) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for ...
Important drug interactions are rare. [38] [39] However, the most significant major drug interaction concern is the decreased activation of clopidogrel when taken together with omeprazole. [40] Although still controversial, [41] this may increase the risk of stroke or heart attack in people taking clopidogrel to prevent these events.
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
In the placebo group, PASI75 was reached in 4% of patients, and PASI100 in none; in the group of patients receiving etanercept, an older anti-psoriasis drug, PASI75 was reached in 48%. Until the 60th study week, 11–44% of ixekizumab treated patients relapsed (again, depending on the dosing scheme), as compared to 84% under placebo.
The drug is protected by patents until 2031. [12] Phase II clinical trials for dose finding purposes were completed in 2007, for an intravenous form [13] and in early 2010, for an oral form. [14] Eli Lilly submitted a new drug application to the U.S. Food and Drug Administration (FDA) in November 2018. [15] Three phase III clinical trials were ...